Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Dow Inc
DOW
|
+$123M |
| 2 |
Newmont
NEM
|
+$77.1M |
| 3 |
Corteva
CTVA
|
+$72.5M |
| 4 |
Amcor
AMCR
|
+$60.2M |
| 5 |
Alibaba
BABA
|
+$47.4M |
Top Sells
| 1 |
DuPont de Nemours
DD
|
+$101M |
| 2 |
Apple
AAPL
|
+$94.5M |
| 3 |
GG
Goldcorp Inc
GG
|
+$78.3M |
| 4 |
Microsoft
MSFT
|
+$77.6M |
| 5 |
Pfizer
PFE
|
+$53.9M |
Sector Composition
| 1 | Technology | 19.94% |
| 2 | Healthcare | 14.68% |
| 3 | Consumer Discretionary | 11.95% |
| 4 | Communication Services | 10.13% |
| 5 | Industrials | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1651
Corcept Therapeutics
CORT
$7.83B
| $2.14M | ﹤0.01% |
192,100
+2,700
| +1% | +$30.1K |
|
|
ADAM
1652
Adamas Trust, Inc. Common Stock
ADAM
$654M
| $2.14M | ﹤0.01% |
86,330
+2,200
| +3% | +$54.6K |
|
1653
AtriCure
ATRC
$1.87B
| $2.14M | ﹤0.01% |
71,700
+8,500
| +13% | +$254K |
|
1654
Innovative Industrial Properties
IIPR
$1.6B
| $2.14M | ﹤0.01% |
+17,300
| New | +$2.14M |
|
1655
Interparfums
IPAR
$3.49B
| $2.13M | ﹤0.01% |
32,100
+700
| +2% | +$46.5K |
|
|
BIG
1656
DELISTED
Big Lots, Inc.
BIG
| $2.13M | ﹤0.01% |
74,506
+1,000
| +1% | +$28.6K |
|
|
KNL
1657
DELISTED
Knoll, Inc.
KNL
| $2.13M | ﹤0.01% |
92,500
+2,500
| +3% | +$57.5K |
|
|
TGI
1658
DELISTED
Triumph Group
TGI
| $2.13M | ﹤0.01% |
92,800
+2,000
| +2% | +$45.8K |
|
|
NP
1659
DELISTED
Neenah, Inc. Common Stock
NP
| $2.12M | ﹤0.01% |
31,400
+700
| +2% | +$47.3K |
|
1660
Huron Consulting
HURN
$2.46B
| $2.12M | ﹤0.01% |
42,000
+900
| +2% | +$45.3K |
|
|
AQUA
1661
DELISTED
Evoqua Water Technologies Corp. Common Stock
AQUA
| $2.12M | ﹤0.01% |
148,600
+13,500
| +10% | +$192K |
|
1662
Garrett Motion
GTX
$2.69B
| $2.11M | ﹤0.01% |
137,700
+2,800
| +2% | +$43K |
|
1663
OR Royalties Inc.
OR
$6.75B
| $2.11M | ﹤0.01% |
202,830
-10,300
| -5% | -$107K |
|
|
PRFT
1664
DELISTED
Perficient Inc
PRFT
| $2.11M | ﹤0.01% |
61,600
| – | – |
|
1665
Coherus Oncology, Inc. Common Stock
CHRS
$155M
| $2.1M | ﹤0.01% |
94,900
+14,300
| +18% | +$316K |
|
1666
Esperion Therapeutics
ESPR
$563M
| $2.09M | ﹤0.01% |
44,900
+900
| +2% | +$41.9K |
|
1667
Patrick Industries
PATK
$3.79B
| $2.09M | ﹤0.01% |
63,713
+1,950
| +3% | +$63.9K |
|
1668
Tompkins Financial
TMP
$1.02B
| $2.09M | ﹤0.01% |
25,600
+600
| +2% | +$49K |
|
1669
Apogee Enterprises
APOG
$941M
| $2.09M | ﹤0.01% |
48,000
-3,400
| -7% | -$148K |
|
1670
Tilray
TLRY
$1.16B
| $2.08M | ﹤0.01% |
+44,700
| New | +$2.08M |
|
1671
Bandwidth Inc
BAND
$494M
| $2.08M | ﹤0.01% |
+27,700
| New | +$2.08M |
|
|
CLDR
1672
DELISTED
Cloudera, Inc.
CLDR
| $2.08M | ﹤0.01% |
394,813
+10,700
| +3% | +$56.3K |
|
|
SYKE
1673
DELISTED
SYKES Enterprises Inc
SYKE
| $2.08M | ﹤0.01% |
75,623
+1,600
| +2% | +$43.9K |
|
1674
ODP
ODP
$641M
| $2.07M | ﹤0.01% |
100,660
+10,910
| +12% | +$225K |
|
1675
Veritex Holdings
VBTX
$1.88B
| $2.07M | ﹤0.01% |
79,917
-3,100
| -4% | -$80.5K |
|